| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Pharmacyclics LLC v. Hetero USA Inc., 19-0014 (D. Del.) | Jan. 4, 2019 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib capsules) | 10,106,548 |
| Valeant Pharms. North America LLC v. Strides Pharma Inc., 19-0133 (D.N.J.) | Jan. 4, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 19-0143 (D.N.J.) | Jan. 4, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 9,993,467 |
| Arbor Pharms., LLC v. Teva Pharms. USA, Inc., 19-0053 (D. Del.) | Jan. 9, 2019 | Hon. Colm F. Connolly | Sklice® (ivermectin lotion) | 8,791,153 8,927,595 |
| Bristol-Myers Squibb Co. v. Unichem Labs., Ltd., 19-0055 (D. Del.) | Jan. 9, 2019 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 |
| Sun Pharm. Indus. Ltd. v. Novartis Pharms. Corp., 19-0276 (D.N.J.) | Jan. 9, 2019 | Hon. Susan D. Wigenton | Jadenu® (deferasirox tablets) | 9,283,209 |
| Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp., IPR2019-00554 (PTAB) | Jan. 9, 2019 | N/A | Onpattro® (patisiran sodium for injection) | 8,058,069 |
| Onyx Therapeutics, Inc. v. Breckenridge Pharm., Inc., 19-0071 (D. Del.) | Jan. 11, 2019 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042 7,737,112 8,207,125 |
| Genentech, Inc. v. Laurus Labs Ltd., 19-0078 (D. Del.) | Jan. 14, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Gilead Sciences, Inc. v. Zydus Pharms. (USA) Inc., 19-0529 (D.N.J.) | Jan. 15, 2019 | Hon. Brian R. Martinotti | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) | 6,642,245 6,703,396 8,592,397 8,716,264 9,457,036 9,744,181 |
| Genentech, Inc. v. Aurobindo Pharma Ltd., 19-0103 (D. Del.) | Jan. 17, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Genentech, Inc. v. Laurus Labs Ltd., 19-0104 (D. Del.) | Jan. 17, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Genentech, Inc. v. Aurobindo Pharma Ltd., 19-0105 (D. Del.) | Jan. 17, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 9,561,217 |
| Beloteca, Inc. v. Apicore US LLC, 19-0360 (N.D. Ill.) | Jan. 17, 2019 | Hon. John J. Tharp, Jr. | Lymphazurin® (isosulfan blue for injection) | 7,662,992 8,969,616 9,353,050 |
| Genentech, Inc. v. Lupin Ltd., 19-0109 (D. Del.) | Jan. 18, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Genentech, Inc. v. Lupin Ltd., 19-0110 (D. Del.) | Jan. 18, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Genentech, Inc. v. Micro Labs Ltd., 19-0111 (D. Del.) | Jan. 18, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Genentech, Inc. v. Apotex Inc., 19-0120 (D. Del.) | Jan. 22, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Genentech, Inc. v. Apotex Inc., 19-0123 (D. Del.) | Jan. 22, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 9,561,217 |
| Par Pharm., Inc. v. Pfizer Inc., 19-0615 (S.D.N.Y.) | Jan. 22, 2019 | Hon. William H. Pauley, III | Chantix® (varenicline tartrate tablets) | 6,890,927 7,265,119 |
| Genentech, Inc. v. Shilpa Medicare Ltd., 19-0130 (D. Del.) | Jan. 23, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 8,383,150 8,778,947 |
| Genentech, Inc. v. SciGen Pharms. Inc., 19-0131 (D. Del.) | Jan. 23, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 8,383,150 9,561,217 |
| Genentech, Inc. v. SciGen Pharms. Inc., 19-0132 (D. Del.) | Jan. 23, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 8,383,150 8,420,674 7,767,225 7,988,994 8,753,679 |
| Valeant Pharms. North America LLC v. Cipla Ltd., 19-0988 (D.N.J.) | Jan. 23, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Valeant Pharms. North America LLC v. Teva Pharms. USA, Inc., 19-0990 (D.N.J.) | Jan. 23, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Genentech, Inc. v. Teva Pharms. USA, Inc., 19-0136 (D. Del.) | Jan. 24, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Taro Pharm. Indus. Ltd. v. Novitium Pharma, LLC, 19-1028 (D.N.J.) | Jan. 24, 2019 | Hon. Freda L. Wolfson | Ovide® (malathion lotion) | 7,560,445 7,977,324 |
| Japan Tobacco Inc. v. Mylan Pharms. Inc., 19-0012 (N.D.W.V.) | Jan. 24, 2019 | Hon. Irene M. Keeley | Stribild® (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate tablets) | 8,633,219 |
| Genentech, Inc. v. Accord Healthcare, Inc., 19-0141 (D. Del.) | Jan. 25, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Genentech, Inc. v. Accord Healthcare, Inc., 19-0142 (D. Del.) | Jan. 25, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Pharmacyclics LLC v. Zydus Worldwide DMCC, 19-0143 (D. Del.) | Jan. 25, 2019 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib capsules) | 7,514,444 8,008,309 8,697,711 8,735,403 8,957,079 9,181,257 8,754,091 8,497,277 8,952,015 8,476,284 8,754,090 9,296,753 9,725,455 10,125,140 10,106,548 |
| Genentech, Inc. v. Macleods Pharms. Ltd., 19-0154 (D. Del.) | Jan. 28, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) |
7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Genentech, Inc. v. Granules Pharms., Inc., 19-0164 (D. Del.) | Jan. 28, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 8,383,150 8,420,674 8,778,947 |
| Genentech, Inc. v. Alembic Pharms., Ltd., 19-0177 (D. Del.) | Jan. 29, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Genentech, Inc. v. Hetero Labs Ltd., 19-0178 (D. Del.) | Jan. 29, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Genentech, Inc. v. Amneal Pharms. LLC, 19-0190 (D. Del.) | Jan. 30, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Genentech, Inc. v. Amneal Pharms. LLC, 19-0195 (D. Del.) | Jan. 30, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Galephar Pharm. Research, Inc. v. Upsher-Smith Labs., LLC, 19-2546 (D.N.J.) | Jan. 30, 2019 | Hon. Madeline Cox Arleo | Absorica® (isotretinoin capsules) | 7,435,427 8,367,102 8,952,064 9,078,925 9,089,534 |
| Genentech, Inc. v. Sandoz, Inc., 19-0202 (D. Del.) | Jan. 31, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 9,561,217 |
| Genentech, Inc. v. Sandoz, Inc., 19-0203 (D. Del.) | Jan. 31, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone capsules) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 7,696,236 7,767,225 7,988,994 8,753,679 |
| Genentech, Inc. v. MSN Labs. Private Ltd., 19-0205 (D. Del.) | Jan. 31, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 8,383,150 8,778,947 |
| Biogen Int’l GmbH v. Hetero USA Inc., 19-0211 (D. Del.) | Jan. 31, 2019 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,619,001 |
| Genentech, Inc. v. Cipla Ltd., 19-0219 (D. Del.) | Feb. 1, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Keryx Biopharmaceuticals, Inc. v. Chemo Research S.L., 19-0220 (D. Del.) | Feb. 1, 2019 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) | 5,753,706 7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,387,191 9,757,416 |
| Leo Pharma A/S v. Taro Pharms. U.S.A., 19-0221 (D. Del.) | Feb. 1, 2019 | Hon. Colm F. Connolly | Finacea® (azelaic acid foam) | 7,700,076 8,435,498 8,722,021 8,900,554 9,211,259 9,265,725 10,117,812 |
| Genentech, Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-0223 (D. Del.) | Feb. 1, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 7,566,729 7,635,707 7,767,700 7,816,383 7,910,610 8,013,002 8,084,475 8,318,780 8,383,150 8,420,674 8,592,462 8,609,701 8,648,098 8,754,109 8,778,947 |
| Par Pharm., Inc. v. Merck Sharp & Dohme Corp., 19-4432 (D.N.J.) | Feb. 1, 2019 | Hon. Madeline Cox Arleo | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) | 7,326,708 |
| Leo Pharma A/S v. Taro Pharms. U.S.A., 19-1051 (S.D.N.Y.) | Feb. 4, 2019 | Hon. Colleen McMahon | Finacea® (azelaic acid foam) | 7,700,076 8,435,498 8,722,021 8,900,554 9,211,259 9,265,725 10,117,812 |
| Genzyme Corp. v. Zenara Pharma Private Ltd., 19-0264 (D. Del.) | Feb. 7, 2019 | Hon. Colm F. Connolly | Cerdelga® (eliglustat capsules) | 6,916,802 7,196,205 7,253,185 7,615,573 |
| Corcept Therapeutics Inc. v. Teva Pharms. USA, Inc., 19-5066 (D.N.J.) | Feb. 8, 2019 | Hon. Susan D. Wigenton | Korlym® (mifepristone tablets) | 10,166,242 10,166,243 10,195,214 |
| Genzyme Corp. v. Zenara Pharma Private Ltd., 19-5160 (D.N.J.) | Feb. 8, 2019 | Hon. Brian R. Martinotti | Cerdelga® (eliglustat capsules) | 6,916,802 7,196,205 7,253,185 7,615,573 |
| Valeant Pharms. North America LLC v. Zydus Pharms. (USA) Inc., 19-5162 (D.N.J.) | Feb. 8, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Biogen Int’l GmbH v. Accord Healthcare Inc., 19-0303 (D. Del.) | Feb. 12, 2019 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,619,001 |
| Meda Pharms. Inc. v. Aurobindo Pharma Ltd., 19-5501 (D.N.J.) | Feb. 12, 2019 | Hon. Brian R. Martinotti | Astepro® (azelastine HCl nasal spray) | 8,071,073 8,518,919 9,919,050 |
| Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC, 19-0310 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Anchen Pharms., Inc., 19-0311 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Sandoz Inc., 19-0312 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) Januvia® (sitagliptin phosphate) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Apotex Inc., 19-0313 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) Januvia® (sitagliptin phosphate) Janumet® (sitagliptin phosphate / metformin HCl) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Zydus Pharms. (USA) Inc., 19-0314 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) Januvia® (sitagliptin phosphate) Janumet® (sitagliptin phosphate / metformin HCl) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Mylan Pharms. Inc., 19-0315 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Januvia® (sitagliptin phosphate) | 7,326,708 8,414,921 |
| Merck Sharp & Dohme Corp. v. Macleods Pharms. Ltd., 19-0316 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Januvia® (sitagliptin phosphate) Janumet® (sitagliptin phosphate / metformin HCl) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Watson Labs., Inc., 19-0317 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Januvia® (sitagliptin phosphate) | 7,326,708 8,414,921 |
| Merck Sharp & Dohme Corp. v. Teva Pharms. USA, Inc., 19-0318 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) Januvia® (sitagliptin phosphate) Janumet® (sitagliptin phosphate / metformin HCl) Juvisync® (simvastatin/ sitagliptin phosphate) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Sun Pharma Global FZE, 19-0319 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) Januvia® (sitagliptin phosphate) Janumet® (sitagliptin phosphate / metformin HCl) | 7,326,708 8,414,921 |
| Merck Sharp & Dohme Corp. v. Torrent Pharms. Ltd., 19-0320 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Januvia® (sitagliptin phosphate) | 7,326,708 |
| Merck Sharp & Dohme Corp. v. Wockhardt Bio AG, 19-0321 (D. Del.) | Feb. 13, 2019 | Hon. Richard G. Andrews | Januvia® (sitagliptin phosphate) Janumet® (sitagliptin phosphate / metformin HCl) | 7,326,708 |
| Genentech, Inc. v. Torrent Pharms. Ltd., 19-0324 (D. Del.) | Feb. 14, 2019 | Hon. Richard G. Andrews | Esbriet® (pirfenidone tablets) | 8,383,150 8,778,947 |
| Celgene Corp. v. Hetero Labs Ltd., 19-5797 (D.N.J.) | Feb. 14, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,093,647 10,093,648 10,093,649 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 19-5799 (D.N.J.) | Feb. 14, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,093,647 10,093,648 10,093,649 |
| Celgene Corp. v. Mylan Pharms. Inc., 19-5802 (D.N.J.) | Feb. 14, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,093,647 10,093,648 10,093,649 |
| Celgene Corp. v. Breckenridge Pharm., Inc., 19-5804 (D.N.J.) | Feb. 14, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,093,647 10,093,648 10,093,649 |
| Celgene Corp. v. Apotex Inc., 19-5806 (D.N.J.) | Feb. 14, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,093,647 10,093,648 10,093,649 |
| Valeant Pharms. North America LLC v. Apotex Inc., 19-5939 (D.N.J.) | Feb. 15, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Biogen Int’l GmbH v. Zydus Pharms. (USA) Inc., 19-5987 (D.N.J.) | Feb. 15, 2019 | Hon. Brian R. Martinotti | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,619,001 |
| Merck Sharp & Dohme Corp. v. Lupin Ltd., 19-0347 (D. Del.) | Feb. 19, 2019 | Hon. Richard G. Andrews | Janumet® (sitagliptin phosphate / metformin HCl) | 7,326,708 |
| Galderma Labs. L.P. v. Teva Pharms. USA, Inc., 19-0351 (D. Del.) | Feb. 19, 2019 | Hon. Richard G. Andrews | Soolantra® (ivermectin cream) | 10,206,939 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000685 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,211,253 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000686 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,211,253 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000687 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,211,253 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000688 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,468,747 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000689 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,468,747 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000690 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,468,747 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000691 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,561,177 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000692 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,561,177 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000693 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,561,177 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000694 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,629,965 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000695 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,629,965 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000696 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,629,965 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000697 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,775,838 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000698 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,775,838 |
| Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000699 (PTAB) | Feb. 19, 2019 | N/A | Narcan® (naloxone HCl nasal spray) | 9,775,838 |
| Celgene Corp. v. Apotex Inc., 19-6999 (D.N.J.) | Feb. 26, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,189,740 8,404,717 9,056,120 |
| Mitsubishi Tanabe Pharma Corp. v. Lupin Ltd., 19-7165 (D.N.J.) | Feb. 27, 2019 | Hon. Peter G. Sheridan | Invokamet XR® (canagliflozin / metformin HCl extended-release tablets) | 7,943,582 8,513,202 |
| Valeant Pharms. North America LLC v. Macleods Pharms. Ltd., 19-7296 (D.N.J.) | Feb. 28, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Pharmacyclics LLC v. Alvogen Pine Brook LLC, 19-0434 (D. Del.) | Mar. 1, 2019 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib capsules) | 7,514,444 8,008,309 8,476,284 8,497,277 8,697,711 8,735,403 8,754,090 8,754,091 8,952,015 8,957,079 9,181,257 9,296,753 9,655,857 9,725,455 10,010,507 10,106,548 10,125,140 |
| Endo Pharms. Inc. v. Perrigo UK Finco Ltd., 19-0437 (D. Del.) | Mar. 1, 2019 | Hon. Maryellen Noreika | Nascobal® (cyanocobalamin nasal spray) | 7,229,636 7,404,489 7,879,349 8,003,353 8,940,714 9,415,007 |
| Cipla Ltd. v. AstraZeneca AB, 19-0438 (D. Del.) | Mar. 1, 2019 | Hon. Maryellen Noreika | Nexium® (esomeprazole magnesium delayed-release oral suspension) | 6,428,810 |
| Galderma Labs., L.P. v. Amneal Pharms. LLC, 19-0440 (D. Del.) | Mar. 1, 2019 | Hon. Leonard P. Stark | Oracea® (doxycycline capsules) | 10,058,564 |
| Biodelivery Sciences Int’l, Inc. v. Chemo Research, S.L., 19-0444 (D. Del.) | Mar. 1, 2019 | Hon. Colm F. Connolly | Belbuca® (buprenorphine buccal film) | 8,147,866 9,655,843 9,901,539 |
| Sun Pharm. Indus. Ltd. v. Vistapharm, Inc., 19-7536 (D.N.J.) | Mar. 1, 2019 | Hon. Stanley R. Chesler | Riomet® (metformin HCl oral solution) | 6,890,957 |
| Apicore US LLC v. Beloteca, Inc., 19-0077 (E.D. Tex.) | Mar. 4, 2019 | Hon. Rodney Gilstrap | Isosulfan blue for injection | 8,969,616 9,353,050 |
| Sawai USA, Inc. v. Biogen MA, Inc., IPR2019-00789 (PTAB) | Mar. 4, 2019 | N/A | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Millennium Pharms., Inc. v. Aurobindo Pharma USA Inc., 19-0471 (D. Del.) | Mar. 6, 2019 | Hon. Colm F. Connolly | Velcade® (bortezomib for injection) | 6,713,446 6,958,319 |
| UCB, Inc. v. Actavis Labs. UT, Inc., 19-0474 (D. Del.) | Mar. 6, 2019 | Hon. Leonard P. Stark | Neupro® (rotigotine transdermal system) | 10,130,589 |
| Valeant Pharms. North America LLC v. Slayback Pharma, LLC, 19-8218 (D.N.J.) | Mar. 8, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 19-8233 (D.N.J.) | Mar. 8, 2019 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 19-0037 (N.D.W.V.) | Mar. 11, 2019 | Hon. Thomas S. Kleeh | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Pfizer Inc. v. Ajanta Pharma Ltd., 19-0517 (D. Del.) | Mar. 15, 2019 | Hon. Leonard P. Stark | Xeljanz® (tofacitinib tablets) | 6,965,027 RE41,783 |
| Biodelivery Sciences Int’l, Inc. v. Chemo Research, S.L., 19-8660 (D.N.J.) | Mar. 15, 2019 | Hon. Kevin McNulty | Belbuca® (buprenorphine buccal film) | 8,147,866 9,655,843 9,901,539 |
| Keryx Biopharmaceuticals, Inc. v. Mylan Pharms. Inc., 19-0040 (N.D.W.V.) | Mar. 15, 2019 | Hon. Thomas S. Kleeh | Auryxia® (ferric citrate tablets) | 5,753,706 7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,387,191 9,757,416 |
| Celgene Corp. v. Teva Pharms. USA, Inc., 19-8758 (D.N.J.) | Mar. 19, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,093,647 10,093,648 10,093,649 |
| Mayne Pharma Int’l Pty Ltd. v. Prinston Pharm. Inc., 19-0549 (D. Del.) | Mar. 21, 2019 | Hon. Richard G. Andrews | Doryx® MPC (doxycycline hyclate delayed-release tablets) | 9,295,652 9,446,057 9,511,031 |
| Sandoz Inc. v. Pharmacyclics LLC, IPR2019-00865 (PTAB) | Mar. 21, 2019 | N/A | Imbruvica® (ibrutinib tablets) Imbruvica® (ibrutinib capsules) | 9,795,604 |
| Mallinckrodt Hospital Products IP Ltd. v. Altan Pharma Ltd., 19-0552 (D. Del.) | Mar. 22, 2019 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,399,012 9,610,265 9,987,238 6,992,218 |
| Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 19-0560 (D. Del.) | Mar. 22, 2019 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,149,829 |
| Indivior Inc. v. Aveva Drug Delivery Systems, Inc., 19-60757 (S.D. Fla.) | Mar. 22, 2019 | Hon. Beth Bloom | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 8,017,150 8,603,514 9,687,454 9,931,305 |
| Boehringer Ingelheim Pharma GmbH & Co. KG v. Aurobindo Pharma Ltd., 19-8840 (D.N.J.) | Mar. 22, 2019 | Hon. Brian R. Martinotti | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Eli Lilly and Co. v. Dr. Reddy’s Labs., Ltd., 19-1246 (S.D. Ind.) | Mar. 27, 2019 | Hon. Jane Magnus-Stinson | Alimta® (pemetrexed for injection) | 7,772,209 |
| Eagle Pharms., Inc. v. Accord Healthcare, Inc., 19-0344 (M.D.N.C.) | Mar. 27, 2019 | Hon. William L. Osteen, Jr. | Argatroban Injections | 7,589,106 7,687,516 |
| Eagle Pharms., Inc. v. Accord Healthcare, Inc., 19-9031 (D.N.J.) | Mar. 27, 2019 | Hon. Claire C. Cecchi | Argatroban Injections | 7,589,106 7,687,516 |
↧
New ANDA Cases
↧
